छत्तीसगढ़ में एक टैंक की सफाई करते समय कथित तौर पर गैस रिसाव होने के बाद पेपर मिल के सात श्रमिकों को अस्पताल में भर्ती कराया गया है।

President Donald Trump’s re-election campaign launched a massive, multi-million dollar ad blitz against presumptive Democratic presidential nominee Joe Biden on Thursday, its biggest onslaught against Biden since the coronavirus pandemic hit the United States.

The Trump campaign released a new ad in Spanish targeting Democrats for their response to the allegations Tara Reade made against presumptive Democratic nominee Joe Biden.

After teasing it for seven months, President Donald Trump’s re-election campaign finally launched a new phone application to rally supporters on Thursday that has been re-imagined for the virtual political age.

Joe Biden's campaign has signed a joint fundraising agreement with the DNC that will help Democrats close the gap with President Donald Trump's massive war chest.

The unified anti-Trump effort has already spent millions on attacking the Trump administration's handling of the virus, or praising former Vice President Joe Biden on the issue.

President Trump new coronavirus TV ad hits critics like Joe Biden and Nancy Pelosi, argues America writing the 'the greatest comeback story'

Unite the Country, a super PAC supporting Joe Biden, and the Trump campaign both launched $10 million ad campaigns this week.

President Trump's reelection campaign trashed Facebook's new oversight board in a statement alleging anti-Trump bias by the social media platform.

Earlier this week, Facebook revealed the first 20 members of its new oversight board, which has responsibility for content enforcement and governance on its platforms. The board includes Pamela Karlan, ...

Rep. Justin Amash believes his White House bid is bad for both President Trump and his Democratic challenger, the Michigan Libertarian indicated in a recent interview.

Mr. Amash, a former Republican who left the GOP last year, told Time that he expects his presence in the presidential race will not ...

You can donate here at: virginmoneygiving.com/fund/FoodforLondonNOW

Read our live coronavirus updates HERE

You can donate at: virginmoneygiving.com/fund/FoodforLondonNOW

Read our live coronavirus updates HERE

The heir to the throne, 71, spent seven days self isolating at his Scottish home Birkhall, when he was told he had contracted the disease late last month.

"Our premise has always been to change an industry which is traditionally quite bad, and become sustainable"

The Bishop of London tells April Roach there has never been a greater need for people to come together to help feed hungry Londoners You can donate here virginmoneygiving.com/fund/FoodforLondonNOW

Jack Peagam is livestreaming the event on Facebook

The NHS is launching a campaign encouraging ill people to seek urgent care during the coronavirus outbreak after A&E visits dropped by 50 per cent this month.

Deaf campaigners have begun legal proceedings against the Government over the lack of sign language interpreters during the daily coronavirus briefings.

Captain Tom Moore has now raised a staggering £30m for the NHS in its battle against coronavirus as he celebrates his 100th birthday.

A key figure of Columbia Road flower market and a campaigning businessman dubbed "Mr Highbury" are among the latest victims whose deaths show how coronavirus is tearing through London's communities.

You can donate at virginmoneygiving.com/fund/FoodforLondonNOW

Police have dropped an investigation into two prominent Brexit campaigners accused of breaching spending rules during the referendum campaign. In 2018 the Electoral commission said that Alan Halsall, of Vote Leave, and Darren Grimes, founder of pro-Brexit youth group BeLeave, failed to declare a payment related to the campaign. The watchdog said that BeLeave "spent more than £675,000 with (Canadian data firm) Aggregate IQ under a common plan with Vote Leave". This spending took Vote Leave over its £7 million legal spending limit by almost £500,000. Vote Leave paid a £61,000 fine, but denied wrongdoing, while Mr Grimes won an appeal against his £20,000 fine in July. The Commission also referred the pair to the Metropolitan Police but on Friday it was revealed that the investigations had now been dropped. A spokesman for the Leave campaigners said: "The Metropolitan Police has written to Vote Leave board member Alan Halsall and BeLeave founder Darren Grimes to confirm that it will not be acting on allegations made against them by the Electoral Commission and various Remain campaigners. "This marks the end of a two-year ordeal for both individuals." Mr Grimes, 26, said the development called into question whether the Electoral Commission was "fit for purpose". He had insisted since the allegations were first made that he was "completely innocent" of making false declarations in relation to the £680,000 donation. In a statement, Mr Grimes, a former fashion student originally from County Durham, said: "The Metropolitan Police has found, after investigation and consultation with the Crown Prosecution Service, that there is no case to be answered. "Once again the Electoral Commission has been found to be part of the mob, a quango out of control that isn't policing elections so much as punishing Leavers who have the temerity to win them. "My ordeal at the hands of the kangaroo court that is the Electoral Commission is now over, but questions must now be asked of whether that body is fit for purpose." Mr Halsall, the responsible person for Vote Leave, said he was "delighted to have been exonerated" and thanked the police for their "professional" investigation. "I was very disappointed that my colleagues at Vote Leave and myself were never given the opportunity of making our case in person to the Electoral Commission before being fined and reported to the police," he added. "It seems a rather unusual way of conducting an inquiry into such matters that only the so-called whistleblowers who made these allegations are interviewed by the regulator." A spokesman for the Met said an investigation into the Electoral Commission's allegations against Vote Leave and BeLeave, submitted on July 17 2018, was handed over in October to the Crown Prosecution Service (CPS). "On Tuesday, March 3 preliminary advice was received from the CPS," said the force spokesman. "This advice has now been duly considered and no further action will be taken."

The latest roundup of pandemic findings gathered by Hakai Magazine. 

Related Stories

• BC’s Quick Start on COVID-19 Testing and Targeted Approach Praised (in News)

Students, teachers and community groups are working to ensure that support is still available as the COVID-19 pandemic keeps kids out of school.

Katrina vanden Heuvel

The post The Pandemic Has Made the Poor People’s Campaign Virtual—and Vital appeared first on The Nation.

President Trump and Vice President Pence have made official visits to battleground states this week, while the Biden campaign tries new ways to reach voters in key states virtually.

We love these products, and we hope you do too. E! has affiliate relationships, so we may get a small share of the revenue from your purchases. Items are sold by the retailer, not E!. One...

Jeremy Corbyn's allies have been accused of using a report to "smear whistleblowers" and "discredit allegations" of anti-Semitism in the Labour Party during his tenure.

EXCLUSIVE: Independent candidate withdraws after difficult decision over job 'I really, really dreamed of'

There are many challenges to developing a vaccine that will be successful against COVID-19.eamesBot / Shutterstock

Wayne Koff is one of the world’s experts on vaccine development, the president and CEO of the Human Vaccines Project. He possesses a deep understanding of the opportunities and challenges along the road to a safe and effective vaccine against COVID-19. He has won prestigious awards, published dozens of scientific papers, held major positions in academia, government, industry, and nonprofit organizations. But Koff, 67, has never produced a successful vaccine.

“I have been an abject failure,” he says. He smiles with a charming, self-deprecating sense of humor. “That’s what the message is.”

The real reason for Koff’s lack of success is that he spent most of his career searching for a vaccine against HIV, the virus that causes AIDS. It remains, as he and many others put it, “the perfect storm” of a viral infection resistant to a vaccine development. Almost 40 years after doctors first recognized the disease in five men in Los Angeles—and 70 million people have been infected worldwide—there are no adequate animal models. Neutralizing antibodies, the backbone of many vaccines, do not stop it, and most importantly, HIV begins its assault on the body by attacking CD4 T cells, which serve as the command center of much of the immune system.

As for COVID-19, “We’re all hoping this one is going to be easier,” says Koff, a slight, bearded man with thick, curly salt-and-pepper hair. “There are research issues that still have to be addressed on a COVID vaccine. But they are a lot more straightforward than what we were dealing with in HIV.”

Let’s say we have a vaccine in 18 months. How do you make 1 billion doses or 4 billion doses or whatever it’s going to take to immunize everybody?

Koff and others started the Human Vaccines Project in 2016, modeled on the Human Genome Project. The project works with industry and academia to study the human immune system and develop vaccines, incorporating every modern-day tool, including artificial intelligence, computational biology, and big data sets. Today it is partnered with the Harvard T.H. Chan School of Public Health.

With COVID-19, Koff says, scientists “know the target is the spike protein binding site.” This is where the proteins sticking out from the virus attach to the cells in the human respiratory system. “If you can elicit antibodies against those proteins, they should be neutralizing.” He puts a strong emphasis on should. To prove antibodies will prevent infection, scientists must watch a population of people who’ve been infected for months or longer. It’s a good bet, based on similar viruses, that antibodies will appear and protect—although no one right now can predict how long and how well.

Depending on which count you use, more than 70 companies, universities, and other institutions are offering candidate vaccines. Koff says the real number of companies is lower. During the AIDS crisis, he says, “a lot of people claimed they had an experimental HIV vaccine in development. Some of those were a one-person lab who had created a paper company to attract investors.”

But even with a lower number, almost everyone involved in the search for a vaccine agrees that several different approaches from different research organizations need to proceed in parallel. The world does not have the time to bet on one horse. The race will be neither simple nor cheap.

“The probability of success, depending on whose metric is used in vaccines, is somewhere between 6 and 10 percent of candidate vaccines that make it from the animal model through licensure,” Koff says. “That process costs $1 billion or more. So you can do the math.”

Koff sees big potential problems at the outset. “In the best of all worlds, let’s say we have a vaccine in 18 months. Who knows where the epidemic is going to be then and what its impact is going to be? How do you make 1 billion doses or 4 billion doses or whatever it’s going to take to immunize everybody? Will we need one dose or two or three? These are issues people just haven’t faced before.”

COVID-19 also presents some unique dangers for vaccine safety. Based on how the virus behaves when it infects some people, there’s a chance a vaccine could dangerously overstimulate the immune system, a reaction called immune enhancement. “I’m hoping it’s more theoretical than real,” Koff says. “But that has to be addressed and it may slow down the entire process.” To ensure safety, he says, “It may mean we have to test the vaccine in a larger number of people. It’s one thing to do a 50-person trial in healthy adults as a safety signal. It’s another thing to run a trial of 4,000 or 5000 or more individuals.”

The world does not have the time to bet on one horse. The race will be neither simple nor cheap.

A virus also sometimes causes mysterious, potentially deadly blood clots. This means an experimental vaccine could hypothetically induce the same damage. “This is a bad bug,” Koff says. “We’re just starting to understand that pathogenesis.”

A big question is who should be the first volunteers for widespread vaccine testing. “Who are the high-risk groups?” asks Koff. “Is it nursing-home residents and staff, health-care workers and people on the front lines, or people someplace else like grocery stores? We must also make sure a vaccine is effective for the elderly and people in the developing world.”

Many vaccines work well in young and healthy people but not in older adults because immunity declines with age. Influenza vaccine is a prime example. Rotavirus vaccine, which protects against the deadliest killer—diarrheal disease in children—works better in the developed world. In the developing world, the virus often circulates year-round. Infants get antibodies from breast milk but not enough to prevent disease. Worse, those antibodies can make the vaccine less effective.

Another hypothetical obstacle is that a mutation in the COVID-19 virus could render a vaccine designed today less effective in the future. While the virus mutates frequently, so far there has been little change in the critical part of the spike that binds to human cells.

Of course, neither Koff nor all the others working for a COVID-19 vaccine focus solely on the potential obstacles. At one time, all vaccines against viruses either killed viruses, such as the Salk polio vaccine, or rendered them harmless, such as the Sabin polio vaccine. Now there is a multiplicity of ways to stimulate an immune response to prevent infection or reduce the consequences. These include genetically engineered protein subunits (peptides) or virus-like particles. Such approaches have led to successful vaccines against hepatitis B and human papilloma virus, which causes cervical cancer. Researchers now use “vectors”—harmless viruses attached to the protein subunits and virus particles to transmit them into the body. There are also many new adjuvants, chemicals that boost immune response to a vaccine.

Newer platforms include direct injection of messenger-RNA. M-RNA is the chemical used to translate the information in DNA into proteins in all cells. The Moderna Company, which received a $483 million grant from the U.S. government, and has begun early clinical trials, uses m-RNA to try to make the body produce proteins to protect against the COVID-19 virus. INOVIO Pharmaceuticals uses pieces of DNA called plasmids to achieve the same objective. It has also begun phase 1 studies.

“There are about eight platforms, and it would be good to see a couple vaccines in each of those advance,” Koff says. Predicting which of these most likely to succeed or fail he says would be “simply foolish.”

Many groups, including the Human Vaccines Initiative, are plotting routes to test any possible vaccine more quickly than tradition dictates with an “adaptive trial design.” Usually trials begin with a phase 1 study of some 50 healthy people to search for any immediate signs of toxicity, then moves onto about 200 people in a phase 2, still looking for hazards and a signal of immunity, and then to phase 3 in thousands of people. But the plan here is to start phases 2 and 3 even before its predecessors are finished, and keep recruiting additional volunteers so long as no danger signals arise.

Good animal models are appearing almost daily. Macaque monkeys, hamsters, and genetically engineered mice have all been infected in the laboratory and could determine whether potential vaccines exhibit various types of immunity. Members of Congress from both sides of the aisle have suggested that healthy human volunteers should be allowed to agree to be test subjects, allowing themselves to be infected. Stanley Plotkin, a vaccine researcher at the University of Pennsylvania, was among the first to suggest the idea.

Arthur Caplan, a bioethicist at New York University, says that “deliberately causing disease in humans is normally abhorrent.” But COVID-19 is anything but a normal circumstance. In this case, Caplan says, “asking volunteers to take risks without pressure or coercion is not exploitation but benefitting from altruism.” At least 1,500 people have already volunteered to be such human guinea pigs, although none of the experimental vaccines is far enough along to try such challenging experiments.

Koff says the key to a successful vaccine is a cooperative effort. “It’s going to take a whole different way of thinking to move this onto the expedited train,” he says. “The old dog-eat-dog, ‘I’m going to beat you to the end of the game,’ isn’t going to help us with this.” Seth Berkley, who worked with Koff at the International AIDS Vaccine Initiative, and now heads GAVI, an international vaccine organization, agrees that a COVID-19 vaccine needs a Manhattan Project approach. “An initiative of this scale won’t be easy,” Berkley says. “Extraordinary sharing of information and resources will be critical, including data on the virus, the various vaccine candidates, vaccine adjuvants, cell lines, and manufacturing advances.”

Koff has no regrets about spending so many years on an AIDS vaccine without results. He learned a great deal, he says, which he’s putting to work in the COVID-19 crisis. “The reason COVID-19 vaccines should be a lot easier is because most of the platforms, the novel approaches, and the clinical infrastructure for the testing of vaccines, came out of HIV.” He pauses. “We’re far better prepared.”

Robert Bazell is an adjunct professor of molecular, cellular, and developmental biology at Yale. For 38 years, he was chief science correspondent for NBC News.

The show is due to return in September

Turley and her boyfriend Finn Tapp are currently staying with her parents in Scotland

James McAvoy has praised the NHS for saving his life when he suffered a botched surgery.

The couple met while the judge was on the Strictly tour

As she departs the French maison, we mark some of her finest moments

West Ham midfielder Tomas Soucek has made a donation to the 'Wave for Hope' campaign to help his native Czech Republic in their fight against the coronavirus pandemic.

Welcome to the Evening Standard's LIVE coverage as the coronavirus crisis continues to heavily impact sport across the globe.

Welcome to the Evening Standard's LIVE coverage as the coronavirus crisis continues to heavily impact sport across the globe.

Former England captain David Beckham was joined by some of the greatest players of all-time, including Pele and Diego Maradona, in a Fifa campaign to show appreciation for key workers leading the global fight against the coronavirus pandemic.

We love these products, and we hope you do too. E! has affiliate relationships, so we may get a small share of the revenue from your purchases. Items are sold by the retailer, not E!. One...